SCHEMBL14197130

SCHEMBL14197130

CC(C)C(=O)N1CC=C(c2ccc(F)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 7/20 0.58
NPC1 O15118 1/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPT P10636 1/20 0.56
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
CASP3 P42574 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
MAPK1 P28482 1/20 0.49
KCNH2 Q12809 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
QDPR P09417 1/20 0.48
CCR1 P32246 1/20 0.47
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14393509 0.83 QDPR (0.67) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL27694889 0.82 NAMPT (0.55) NAMPTNPC1ALDH1A1ALOX15RAB9A
SCHEMBL4602817 0.81 ALDH1A1 (0.66) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL5542441 0.80 ALDH1A1 (0.60) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL14224507 0.79 MAPK1 (0.58) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL11790812 0.79 ALDH1A1 (0.54) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL2252888 0.79 NPC1 (0.48) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL2546549 0.79 NPC1 (0.48) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL2546779 0.77 MMP1 (0.53) NAMPTNPC1ALDH1A1MAPTHPGD
SCHEMBL2244916 0.77 MMP1 (0.53) NAMPTNPC1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354919-B2 Isoxazole compositions useful as inhibitors of ERK VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-04-08 US disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 NAMPT 1451/4885NPC1 3471/4885ALDH1A1 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.